@article{10.37349/etat.2025.1002317,
abstract = {The role of circulating tumor DNA (ctDNA) in urothelial cancers is a rapidly evolving area of research. Urothelial cancer is the most common subtype of bladder cancer, and biomarkers that predict response or prognosticate outcomes have been long sought after. Tumor-informed ctDNA assays have been utilized in several other cancers and increasingly used in both muscle invasive bladder cancer (MIBC) and metastatic urothelial cancer (mUC) to inform treatment decision-making. While a universal consensus on ctDNA testing has not been fully defined and discussed herein, understanding its benefits and limitations is important to help guide the practical application in the clinic.},
author = {Aragon-Ching, Jeanny B.},
doi = {10.37349/etat.2025.1002317},
journal = {Exploration of Targeted Anti-tumor Therapy},
elocation-id = {1002317},
title = {The role of circulating tumor DNA (ctDNA) in urothelial cancers},
url = {https://www.explorationpub.com/Journals/etat/Article/1002317},
volume = {6},
year = {2025}
}